Anticancer drug discovery and development throughout the world.
This year's American Society of Clinical Oncology International Symposium devoted 2 hours to a lively discussion of various aspects of anticancer drug discovery and development throughout the world. The scientific program started with an overview of efforts directed toward promoting international collaboration in natural product-derived anticancer drug discovery. This was followed by a discussion on the importance of interethnic differences and pharmacogenetics in anticancer drug development. Thereafter, this part of the program was completed by a description of the activities of the newly created Singapore-Hong Kong-Australia Drug Development Consortium and an overview of the contribution of Japan to anticancer drug development. The logistics and regulatory aspects of clinical trials with new anticancer agents in different parts of the world were then presented, with an emphasis on Europe, North America, and Japan. The program was completed with a panel discussion of the efforts to harmonize the exchange of clinical data originating from one region of the globe with other territories, with input from official representatives of the United States Food and Drug Administration and the Medical Devices Evaluation Center of Japan.
Schwartsmann
G
G
South-American Office for Anticancer Drug Development, Lutheran University of Brazil, and Postgraduate Course in Medicine, Federal University of Rio Grande do Sul, Porto Alegre, Brazil. gschwart.ez@terra.com.br
Ratain
M J
MJ
Cragg
G M
GM
Wong
J E
JE
Saijo
N
N
Parkinson
D R
DR
Fujiwara
Y
Y
Pazdur
R
R
Newman
D J
DJ
Dagher
R
R
Di Leone
L
L
D000970:Antineoplastic Agents; D004341:Drug Evaluation; D015507:Drugs, Investigational; D005260:Female; D014943:Global Health; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000453:epidemiology* / Q000517:prevention & control*
D000970:Antineoplastic Agents; D015507:Drugs, Investigational